SELECTA BIOSCIENCES INC
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Selecta Biosciences stock with a target price of $39.75, indicating strong potential growth.
Financial Health
Selecta Biosciences is generating moderate revenue and cash flow, but overall performance is mixed.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RNAC
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: July 11, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and partner announcements can create meaningful share‑price moves, though outcomes are uncertain and can be volatile.
Platform Reach and Partners
The ImmTOR/SVP platforms target multiple therapeutic areas and potential collaborations could extend reach, while commercial success is not guaranteed.
Risk and Volatility
Small‑cap biotech stocks can swing widely on news and financing needs — suitable for investors who accept higher risk and a long time horizon.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
